Single nucleotide polymorphisms (SNPs) in the DNA repair genes are believed to contribute to the clinical outcome of patients receiving platinum-based chemotherapy. We investigated the impact of 2 SNPs of excision repair cross-complementation group 1 and 2 of xeroderma pigmentosum complementation group G on the outcome in patients with non-small-cell lung cancer (NSCLC) treated with platinum-based chemotherapy.
Methods
Between October 2007 and March 2012, we collected 374 blood samples from consecutive patients registered in the TAILOR trial. Four SNPs (rs11615, rs3212986, rs17655, rs1047768) were genotyped using real-time polymerase chain reaction.
Results
The rs11615 polymorphism was associated with histotype (p = 0.0123). No other correlations were found with clinical variables or with EGFR or KRAS mutational status. None of the SNPs had any impact on overall survival or progression-free survival.
Conclusions
The findings suggest that the investigated SNPs do not make any significant contribution to the outcome of NSCLC.
MillerYEPathogenesis of lung cancer: 100 year report. Am J Respir Cell Mol Biol2005;33(3):216–223
2.
DelaCruz CSTanoueLTMatthayRALung cancer: epidemiology, etiology, and prevention. Clin Chest Med2011;32(4):605–644
3.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Non-small cell lung cancer Version 1. 2015 (2014) www.nccn.org. last accessed on 6 December 2014.
4.
ChanBAHughesBGTargeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res2015;4(1):36–54
5.
HarveyRDImmunologic and clinical effects of targeting PD-1 in lung cancer. Clin Pharmacol Ther2014;96(2):214–223
6.
GoldbergSBGettingerSNMahajanAActivity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. J Clin Oncol 33, 2015 suppl; abstr 8035).
7.
BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med2012;366(26):2455–2465
8.
MeloskyBChuQJuergensRLeighlNMcLeodDHirshVPointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. J Clin Oncol2016 May 10;34(14):1676–88
9.
McHughPJSpanswickVJHartleyJARepair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol2001;2(8):483–490
10.
JordheimLPCros-PerrialEMateraELBouledrakKDumontetCExpression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability. Clin Exp Pharmacol Physiol2014;41(10):817–824
11.
DaiCHLiJChenPJiangHGWuMChenYCRNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells. J Biomed Sci2015;22(1):77
12.
ChoiJYParkJMYiJMLeemSHKangTHEnhanced nucleotide excision repair capacity in lung cancer cells by preconditioning with DNA-damaging agents. Oncotarget2015;6(26):22575–22586
13.
HubnerRARileyRDBillinghamLJPopatSExcision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PLoS ONE2011;6(10):e25164
14.
RosellRDanenbergKDAlberolaV; Spanish Lung Cancer Group. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res2004;10(4):1318–1325
15.
ChanECLamSYFuKHKwongYLPolymorphisms of the GSTM1, GSTP1, MPO, XRCC1, and NQO1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the CDKN2A and RARB genes. Cancer Genet Cytogenet2005;162(1):10–20
16.
SeyhanECAltınSCetinkayaEPrognostic significance of ERCC1 expression in resected non small cell lung carcinoma. Ann Thorac Cardiovasc Surg2011;17(2):110–117
17.
BartolucciRWeiJSanchezJJXPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer2009;10(1):47–52
18.
YapTALorenteDOmlinAOlmosDde BonoJSCirculating tumor cells: a multifunctional biomarker. Clin Cancer Res2014;20(10):2553–2568
19.
QinXYaoWLiWERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy. Tumour Biol2014;35(5):4697–4704
20.
XuTPShenHLiuLXShuYQAssociation of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports. Gene2013;526(2):265–274
21.
IslaDSarriesCRosellRSingle nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol2004;15(8):1194–1203
22.
JoergerMBurgersSABaasPGermline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer2012;118(9):2466–2475
23.
YinMYanJVoutsinaANo evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer2011;72(3):370–377
24.
MazzoniFCecereFLMeoniGPhase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer. Lung Cancer2013;82(2):288–293
25.
WeiSZZhanPShiMQPredictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol2011;28(1):315–321
26.
ZhouWGurubhagavatulaSLiuGExcision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res2004;10(15):4939–4943
IranzoVSireraRBremnesRMChemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients. Clin Lung Cancer2011;12(4):224–230
29.
WakasugiMSancarAOrder of assembly of human DNA repair excision nuclease. J Biol Chem1999;274(26):18759–18768
30.
SunXLiFSunNPolymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer2009;65(2):230–236
31.
JinZYZhaoXTZhangLNWangYYueWTXuSFEffects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer. Genet Mol Res2014;13(3):7617–7625
32.
HuWPanJZhaoPYangGYangSGenetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer. Tumour Biol2014;35(6):5561–5567
33.
GarassinoMCMartelliOBrogginiM; TAILOR trialists. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol2013;14(10):981–988
34.
GanzinelliMRulliECaiolaERole of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). Sci Rep2015;5:16331
35.
CaiolaEPorcuLFruscioRDNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer. Pharmacogenomics J2013;13(2):159–172
36.
MarabeseMGanzinelliMGarassinoMCKRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. Oncotarget2015;6(32):34014–34022
37.
HerbstRSHeymachJVLippmanSMLung cancer. N Engl J Med2008;359(13):1367–1380
38.
O'GradySFinnSPCuffeSRichardDJO'ByrneKJBarrMPThe role of DNA repair pathways in cisplatin resistant lung cancer. Cancer Treat Rev2014;40(10):1161–1170
39.
CaiolaEBrogginiMMarabeseMGenetic markers for prediction of treatment outcomes in ovarian cancer. Pharmacogenomics J2014;14(5):401–410
40.
YinMYanJVoutsinaANo evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer2011;72(3):370–377
41.
TiseoMBordiPBortesiB; Bio-FAST trial group. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer2013;108(8):1695–1703
42.
LudoviniVFlorianiIPistolaLAssociation of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. J Thorac Oncol2011;6(12):2018–2026
43.
SunJDengLDuanYInhibitory effect of endostatin combined with paclitaxel-cisplatin on breast cancer in xenograft-bearing mice. Exp Ther Med2012;3(2):159–164
44.
MetroGChiariRMareMCarboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. Cancer Chemother Pharmacol2011;68(6):1405–1412
